BCVM                                                   cervix(41)
 _________________________________________________________________
  bleomycin....... 10 U/sqm/day IV over 7 hours on days 1 to 5.
  cisplatin....... 20 mg/sqm/day IV over 7 hours on days 1 to 5.
  vincristine..... 1 mg/sqm IV on day 1.
  methotrexate.... 40 mg/sqm IV on day 1.
  FREQUENCY....... Repeat cycle every 28 days to a maximum of six 
                   courses.

  reference...
    Rosenthal CJ.  Khulpateea N.  Boyce J.  Mehrotra S.  Tamarin 
    S. Effective chemotherapy for advanced carcinoma of the cervix 
    with bleomycin, cisplatin, vincristine, and methotrexate. 
    Cancer.  52(11):2025-30, 1983 Dec 1. 
  abstract...
    This study was designed as a Phase II clinical trial in 
    advanced recurrent or metastatic squamous cell carcinoma of 
    the cervix with a combination of bleomycin (B: 10 u/m2/d) and 
    cisplatin (P: 20 mg/m2/d) administered for five consecutive 
    days in intravenous infusion for 7 hours and vincristine (V: 1 
    mg/m2) and methotrexate (M: 40 mg/m2) administered only on day 
    one of each cycle which was repeated every 28 days up to a 
    maximum of 6 times. Over a period of 2 years, 15 evaluable 
    patients with measurable disease received at least 3 courses 
    of therapy. Six had recurrent disease and nine had distant 
    metastases. All had previous radiation therapy. There were two 
    dropouts after the first course due to nausea and vomiting 
    which was practically universal. Other side effects included: 
    mild paresthesias of the extremities (89%), stomatitis (41%), 
    diarrhea (17%), moderate pancytopenia and hypomagnesemia which 
    was reduced from 65% to 17% when magnesium sulfate 10% was 
    administered with cisplatin. Sixty-six percent of the 
    evaluable patients achieved remission (7 partial and 3 
    complete) usually before the fourth course of therapy. The 
    disease-free interval was of 29.7 +/- 15 weeks in all 
    responders (40.6 +/- 15.5 weeks in complete responders). The 
    mean survival from the start of BPVM therapy was of 55.8 +/- 
    33.3 weeks in responders and of only 14 +/- 2.9 weeks in 
    nonresponders (P less than 0.01). It is concluded that BPVM is 
    an effective combination chemotherapy in advanced squamous 
    cell carcinoma of the cervix. These results should be 
    confirmed in a Phase III trial.